Abstract: Objective: To investigate the efficacy of terbutaline, glucocorticoids combined with glutathione in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: 92 patients with AECOPD were randomly divided into control group and study group, with 46 cases in each group. The patients in control group were treated with terbutaline and glucocorticoids; the patients in study group were given terbutaline, glucocorticoids combined with glutathione. The clinical efficacy, lung function indexes, blood gas analysis indexes, oxidative stress indexes, and levels of inflammatory factors of patients in 2 groups were compared. Results: The total effective rate of treatment in study group was obviously higher than that in control group (P<0.05). After treatment, the levels of forced expiratory volume in 1 second (FEV1), FEV1/forced vital capacity (FVC)(FEV1/FVC), partial pressure of blood oxygen (PaO₂), arterial oxygen saturation (SaO₂), superoxide dismutase (SOD)of patients in the 2 groups were all obviously increased compared with those before treatment (P<0.05); And after treatment, the above indices of patients in study group were obviously higher than control group (P<0.05). After treatment, the levels of partial pressure of blood carbon dioxide (PaCO₂), 8-iso-prostaglandin-F2α (8-iso-PGF2α), malondialdehyde (MDA), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), C-reactive protein (CRP) and procalcitonin (PCT) of patients in the 2 groups were all significantly decreased compared with those before treatment (P<0.05); And after treatment, the above indices of patients in study group were significantly lower than control group (P<0.05). Conclusions: Treating AECOPD with terbutaline, glucocorticoids combined with glutathione can significantly improve the clinical efficacy, improve the lung function indexes and blood gas analysis indexes, reduce oxidative stress and inflammation, so it has clinical application value.

Key words: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD), Terbutaline, Glucocorticoids, Glutathione

摘要： 目的 探究特布他林、糖皮质激素联合谷胱甘肽治疗慢性阻塞性肺疾病急性加重期（AECOPD）的疗效。方法 92例AECOPD患者随机分为对照组与研究组各46例,对照组予以特布他林联合糖皮质激素治疗,研究组予以特布他林、糖皮质激素联合谷胱甘肽治疗,比较两组患者的临床疗效,肺功能、血气分析指标,氧化应激与炎症因子指标。结果 研究组治疗总有效率明显高于对照组,差异有统计学意义（P<0.05）。治疗后,两组患者第1s用力呼气容积（FEV1）、FEV1/用力肺活量（FVC）（FEV1/FVC）、血氧分压（PaO₂）、血氧饱和度（SaO₂）、超氧化物歧化酶（SOD）水平较治疗前明显升高,且研究组治疗后明显高于对照组,差异有统计学意义（P<0.05）;两组患者血二氧化碳分压（PaCO₂）、8-异前列腺素F2α（8-iso-PGF2α）、丙二醛（MDA）、白介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、C反应蛋白（CRP）、降钙素原（PCT）水平较治疗前明显降低,且研究组治疗后明显低于对照组,差异有统计学意义（P<0.05）。结论 特布他林、糖皮质激素联合谷胱甘肽治疗AECOPD可明显提高疗效,改善患者肺功能、血气分析指标,减轻机体氧化应激及炎症反应,具有临床应用价值。

关键词: 慢性阻塞性肺疾病急性加重期（AECOPD）, 特布他林, 糖皮质激素, 谷胱甘肽